Brain cancer, and in particular Glioblastoma (GB), is a deadly disease that is in critical need of new therapies. We propose to develop biodegradable polymeric gene delivery nanoparticles to treat patients with brain cancer. Based on our recent research on evaluating a library of polymeric nanoparticles for gene delivery, ten lead structures will be synthesized and utilized to non-virally and safely deliver DNA to human Glioblastoma Multiforme (GB) cancer cells. Structure-activity relationships for ten closely related biomaterial analogs and the nanoparticles that they form will be probed in vitro in normal human astrocytes and neurospheres as well human intraoperatively obtained GB cells and GB tumor neurospheres. We hypothesize that through biomaterial and nanoparticle selection, nanoparticles can be targeted to brain cancer cells and cancer stem cells over healthy cells. A nanoparticle system will be created and evaluated in vitro and in vivo to non-virally delivery a gene that induces apoptosis in human brain cancer cells, is benign to healthy human cells, and acts in a paracrine fashion. The non-viral particles enter cells and degrade safely, releasing DNA as therapeutics that causes cancer cell death.
In Aim 1, nanoparticles will be synthesized and characterized and cell assays developed.
In Aim 2, mechanisms of action, cell targeting specificity, and efficacy of the nanoparticles will be evaluated in vitro.
In Aim 3, the top three nanoparticle formulations will be evaluated in vivo in an orthotopic human GB mouse model. The long-term aim of this work is to create a new orthogonal clinical approach to treat Glioblastoma.
This research aims to create new nanbiotechnology to treat Glioblastoma, a common and incurable type of brain cancer. This flexible nanoparticle-mediated gene delivery approach may also be applicable to the treatment of other cancers as well.
|Zamboni, Camila G; Kozielski, Kristen L; Vaughan, Hannah J et al. (2017) Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 263:18-28|
|Li, Xiaowei; Tzeng, Stephany Y; Zamboni, Camila Gadens et al. (2017) Enhancing oligodendrocyte differentiation by transient transcription activation via DNA nanoparticle-mediated transfection. Acta Biomater 54:249-258|
|Wilson, David R; Routkevitch, Denis; Rui, Yuan et al. (2017) A Triple-Fluorophore-Labeled Nucleic Acid pH Nanosensor to Investigate Non-viral Gene Delivery. Mol Ther 25:1697-1709|
|Kosmides, A K; Meyer, R A; Hickey, J W et al. (2017) Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials 118:16-26|
|Airan, Raag D; Meyer, Randall A; Ellens, Nicholas P K et al. (2017) Noninvasive Targeted Transcranial Neuromodulation via Focused Ultrasound Gated Drug Release from Nanoemulsions. Nano Lett 17:652-659|
|Kim, Jayoung; Mirando, Adam C; Popel, Aleksander S et al. (2017) Gene delivery nanoparticles to modulate angiogenesis. Adv Drug Deliv Rev 119:20-43|
|Kozielski, Kristen L; Rui, Yuan; Green, Jordan J (2016) Non-viral nucleic acid containing nanoparticles as cancer therapeutics. Expert Opin Drug Deliv 13:1475-87|
|Mangraviti, Antonella; Tzeng, Stephany Y; Gullotti, David et al. (2016) Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival. Biomaterials 100:53-66|
|Bishop, Corey J; Liu, Allen L; Lee, David S et al. (2016) Layer-by-layer inorganic/polymeric nanoparticles for kinetically controlled multigene delivery. J Biomed Mater Res A 104:707-713|
|Meyer, Randall A; Green, Jordan J (2016) Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:191-207|
Showing the most recent 10 out of 41 publications